DR. BRUCE ROBERT BLAZAR, M.D.
Medical Practice in Minneapolis, MN
License number
Minnesota 25330
Category
Medical Practice
Type
Pediatrics
License number
Minnesota 25330
Category
Medical Practice
Type
Pediatric Hematology-Oncology
Address
Address
516 Pwb Fifth Floor, Minneapolis, MN 55455
Phone
(612) 273-2800
(612) 626-2961
(612) 626-4074 (Fax)
(612) 626-2961
(612) 626-4074 (Fax)
Professional information
Bruce R Blazar, Minneapolis MN
Specialties:
Pediatrics, Pediatric Hematology-Oncology, Transplant Surgery
Work:
University of Minnesota, Twin Cities
420 Delaware St SE, Minneapolis, MN 55455
420 Delaware St SE, Minneapolis, MN 55455
Education:
Albany Medical College (1978)
Multimeric Immunotoxins
US Patent:
6492498, Dec 10, 2002
Filed:
Nov 15, 1999
Appl. No.:
09/440344
Inventors:
Daniel A. Vallera - St. Louis Park MN
Bruce R. Blazar - Golden Valley MN
Bruce R. Blazar - Golden Valley MN
Assignee:
Regents of the University of Minnesota - Minneapolis MN
International Classification:
C07K 1600
US Classification:
5303917, 530300, 530350, 5303871, 4241831
Abstract:
The invention features fusion protein monomers, multimeric immunotoxic proteins, nucleic acids encoding fusion protein monomers, vectors containing the nucleic acids, and cells containing the vectors. Also encompassed by the invention are methods of killing pathogenic cells and making multimeric immunotoxic proteins.
Regulatory T Cells And Their Use In Immunotherapy And Suppression Of Autoimmune Responses
US Patent:
8129185, Mar 6, 2012
Filed:
Dec 29, 2009
Appl. No.:
12/649101
Inventors:
Bruce Blazar - Golden Valley MN, US
Carl June - Merion Station PA, US
Wayne R. Godfrey - Los Altos CA, US
Richard G. Carroll - Lansdowne PA, US
Bruce Levine - Cherry Hill NJ, US
James L. Riley - Downingtown PA, US
Patricia Taylor - St. Paul MN, US
Carl June - Merion Station PA, US
Wayne R. Godfrey - Los Altos CA, US
Richard G. Carroll - Lansdowne PA, US
Bruce Levine - Cherry Hill NJ, US
James L. Riley - Downingtown PA, US
Patricia Taylor - St. Paul MN, US
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
C12N 5/071, C12N 5/00, A01N 63/00
US Classification:
4353723, 435325, 435363, 435366, 424 931, 424 932
Abstract:
Based upon a strong correlation between regulator T cells (Treg cells) and suppressing or preventing a cytotoxic T cell response, provided are methods for the production of ex vivo activated and culture-expanded isolated CD4CD25 suppressor Treg cells for the prevention or suppression of immune reactions in a host, particularly in a human host, and including autoimmune responses. The resulting ex vivo culture-expanded Treg cells provide a sufficient amount of otherwise low numbers of such cells, having long term suppressor capability to permit therapeutic uses, including the preventing, suppressing, blocking or inhibiting the rejection of transplanted tissue in a human or other animal host, or protecting against graft vs host disease. Also provided are therapeutic and immunosuppressive methods utilizing the ex vivo culture-expanded Treg cells for human treatment, and high efficiency methods for research use.
Reducing Inflammation Using Cell Therapy
US Patent:
2013012, May 23, 2013
Filed:
Nov 19, 2009
Appl. No.:
13/510491
Inventors:
Steven L. Highfill - Rockville MD, US
Jakub Tolar - Minneapolis MN, US
Bruce M. Blazar - Golden Valley MN, US
Jakub Tolar - Minneapolis MN, US
Bruce M. Blazar - Golden Valley MN, US
Assignee:
Regents of the University - St Paul MN
International Classification:
A61K 35/12
US Classification:
424 937
Abstract:
The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component, including graft-versus-host disease. The invention is generally directed to reducing inflammation by administering cells that express and/or secrete prostaglandin E2 (PGE2). The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to express and/or secrete PGE2, such as PGE2 receptor agonists. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired levels of PGE2 expression and/or secretion. The invention is also generally directed to delivering cells directly to lymphohematopoietic tissue, such as spleen, lymph nodes, and bone marrow. The invention is, thus, also directed to a method for treating inflammation by administering cells directly into sites of lymphohematopoiesis, such as spleen, lymph nodes, and bone marrow. The administered cells include those that reduce the activation and/or proliferation of T-cells. Such cells may or may not express and/or secrete PGE2.
Compositions And Methods For Detection, Prevention, And Treatment Of Anthrax And Other Infectious Diseases
US Patent:
8192720, Jun 5, 2012
Filed:
Feb 5, 2010
Appl. No.:
12/701149
Inventors:
Thomas Kozel - Reno NV, US
William Murphy - Reno NV, US
Suzanne Brandt - Boise ID, US
Bruce R. Blazar - Golden Valley MN, US
Julie A. Lovchik - Albuquerque NM, US
Peter Thorkildson - Reno NV, US
Ann Percival - Reno NV, US
C. Richard Lyons - Ft. Collins CO, US
William Murphy - Reno NV, US
Suzanne Brandt - Boise ID, US
Bruce R. Blazar - Golden Valley MN, US
Julie A. Lovchik - Albuquerque NM, US
Peter Thorkildson - Reno NV, US
Ann Percival - Reno NV, US
C. Richard Lyons - Ft. Collins CO, US
Assignee:
Board of Regents of the Nevada System of Higher Education, on behalf of the University of Nevada, Reno - Reno NV
International Classification:
A61K 49/00, A61K 39/07, A61K 39/02
US Classification:
424 92, 424 91, 4241301, 4241411, 4241501, 4241641, 4241841, 4242341, 4242461, 435 4, 435 71, 435 72, 436501
Abstract:
Compositions and methods for the detection, prevention, or treatment of anthrax or other infectious diseases. In one aspect, the present invention provides methods for immunizing humans or animals against or other capsulated pathogens. The methods include administering a capsular polypeptide of a pathogen of interest and a CD40 agonist to a human or animal. The capsular polypeptide or the CD40 agonist is administered in such an amount or frequency that an immunoprotective response can be elicited in the human or animal against the pathogen of interest. In another aspect, the present invention provides methods of using passive immunization with anti-capsular polypeptide antibodies to prevent or treat infections caused by or other pathogens. In yet another aspect, the present invention provides methods useful for diagnosis of anthrax by detection of capsular polypeptide in serum or other biological samples.
Compositions And Methods For The Treatment Of Lysosomal Storage Disorders
US Patent:
2007000, Jan 11, 2007
Filed:
Jun 2, 2006
Appl. No.:
11/446560
Inventors:
Bruce Blazar - Golden Valley MN, US
Jakub Tolar - Minneapolis MN, US
Catherine Verfaillie - St. Paul MN, US
Jakub Tolar - Minneapolis MN, US
Catherine Verfaillie - St. Paul MN, US
International Classification:
A61K 48/00
US Classification:
424093210
Abstract:
The present invention relates to methods for providing lysosomal enzymes to a subject by administering stem cells, preferably Multipotent Adult Progenitor Cells (MAPCs). The invention further relates to methods for treating lysosomal storage disorders by administering stem cells.
Generation Of Natural Killer Cells And Lymphoid Tissue Inducer-Like (Lti-Like) Nk-22 Cells
US Patent:
2014007, Mar 13, 2014
Filed:
Dec 2, 2011
Appl. No.:
13/991370
Inventors:
Michael Verneris - Minnetonka MN, US
Jeff Miller - North Oaks MN, US
Bruce Blazar - Golden Valley MN, US
Jeff Miller - North Oaks MN, US
Bruce Blazar - Golden Valley MN, US
Assignee:
REGENTS OF THE UNIVERSITY OF MINNESOTA - St. Paul MN
International Classification:
C12N 5/0783
US Classification:
424 9371, 435375, 435377, 435455
Abstract:
The present invention relates generally to methods to prepare NK and LTi-like, NK22 cells from HSCs and uses of those cells.
Methods To Expand A T Regulatory Cell Master Cell Bank
US Patent:
2013010, Apr 25, 2013
Filed:
Mar 28, 2011
Appl. No.:
13/639927
Inventors:
James L. Riley - Downingtown PA, US
Carl H. June - Merion Station PA, US
Bruce R. Blazar - Golden Valley MN, US
Keli Hippen - Robbinsdale MN, US
Carl H. June - Merion Station PA, US
Bruce R. Blazar - Golden Valley MN, US
Keli Hippen - Robbinsdale MN, US
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
C12N 5/0783
US Classification:
424 9371, 435325, 435375
Abstract:
Compositions and methods for expanding natural T regulatory cells (nTregs) without substantially sacrificing suppressive function of the cells are disclosed. Also provided are uses of the expanded nTregs for cellular therapy.
Methods For Treating Or Preventing Gvhd
US Patent:
2005020, Sep 22, 2005
Filed:
Jan 10, 2005
Appl. No.:
11/032630
Inventors:
Bruce Blazar - Golden Valley MN, US
Matthew O'Shaughnessy - Falcon Heights MN, US
Christine Vogtenhuber - Minneapolis MN, US
Jonathan Serody - Chapel Hill NC, US
Albert Baldwin - Chapel hill NC, US
Matthew O'Shaughnessy - Falcon Heights MN, US
Christine Vogtenhuber - Minneapolis MN, US
Jonathan Serody - Chapel Hill NC, US
Albert Baldwin - Chapel hill NC, US
International Classification:
A61K045/00, C12N005/08
US Classification:
424093710, 435372000
Abstract:
Methods are provided for administering alloreactive T cells to transplant recipients such that the risk of graft-versus-host disease is reduced.
Methods For Preventing Gvhd
US Patent:
2004016, Aug 26, 2004
Filed:
Feb 25, 2003
Appl. No.:
10/374222
Inventors:
Bruce Blazar - Golden Valley MN, US
Matthew O'Shaughnessy - Falcon Heights MN, US
Christine Vogtenhuber - Minneapolis MN, US
Jonathan Serody - Chapel Hill NC, US
Albert Baldwin - Chapel Hill NC, US
Brian Poligone - Palo Alto CA, US
Matthew O'Shaughnessy - Falcon Heights MN, US
Christine Vogtenhuber - Minneapolis MN, US
Jonathan Serody - Chapel Hill NC, US
Albert Baldwin - Chapel Hill NC, US
Brian Poligone - Palo Alto CA, US
International Classification:
A61K045/00, C12N005/08
US Classification:
424/093700, 435/372000
Abstract:
Methods are provided for administering alloreactive T cells to transplant recipients such that the risk of graft-versus-host disease is reduced.